Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 549-557

  Yim, Eun Kyoung ^a,b   Tong, Seo Yun ^a,c   Ho, Eun Mi ^a   Bae, Jeong Hoon ^a   Um, Soo Jong ^d   Park, Jong Sup ^a  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Kyung Hee University Hospital   (South Korea)

^d Sejong University   (South Korea)

Author keywords

CDNA microarray; Cervical cancer cells; Chemo resistance; Paelitaxel; TACC3

Indexed keywords

CD31 ANTIGEN; CELL PROTEIN; GELATINASE B; LIPOCORTIN 2; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PACLITAXEL; PEPTIDYLPROPYL ISOMERASE A; POLO LIKE KINASE 1; PROSTAGLANDIN E RECEPTOR; PROTEIN KINASE B; PROTEIN RAB31; PROTEIN UHRF1; SMALL INTERFERING RNA; THYMOSIN BETA10; TRANSFORMING ACIDIC COILED COIL PROTEIN 3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MICROTUBULE ASSOCIATED PROTEIN; TACC3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UNINDEXED SEQUENCE; UTERINE CERVIX CARCINOMA; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; GENE EXPRESSION; GENETICS; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HELA CELLS; HUMAN PAPILLOMAVIRUS 18; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PAPILLOMAVIRUS INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; UTERINE CERVICAL NEOPLASMS;

EID: 62849099323     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000256     Document Type: Article

References (40)

1. Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265, 2004.
2. Lee KH, Yim EK, Kim CJ, Namkoong SE, Um SJ and Park JS: Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol 98: 45-53, 2005.
3. Ferlini C, Raspaglio G, Mozzetti S, et al: The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res 65: 2397-2405, 2005.
4. Berrieman HK, Lind MJ and Cawkwell L: Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 5: 158-164, 2004.
5. van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM and Giaccone G: Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 5: 249-255, 1998.
6. Goncalves A, Braguer D, Kamath K, et al: Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 98: 11737-11742, 2001.
7. L'Esperance S, Popa I, Bachvarova M, et al: Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 29: 5-24, 2006.
8. Still IH, Hamilton M, Vince P, Wolfman A and Cowell JK: Cloning of TACC1, an embryonically expressed, potentially transforming coiled coil containing gene, from the 8p11 breast cancer amplicon. Oncogene 18: 4032-4038, 1999.
9. Still IH, Vince P and Cowell JK: The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics 58: 165-170, 1999.
10. McKeveney PJ, Hodges VM, Mullan RN, et al: Characterization and localization of expression of an erythropoietin-induced gene, ERIC-1/ TACC3, identified in erythroid precursor cells. Br J Haematol 112: 1016-1024, 2001.
11. Piekorz RP, Hoffmeyer A, Duntsch CD, et al: The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J 21: 653-664, 2002.
12. Schneider L, Essmann F, Kletke A, et al: TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21WAF-mediated cell cycle arrest. Oncogene 27: 116-125, 2008.
13. Debernardis D, Sire EG, De Feudis P, et al: p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57: 870-874, 1997.
14. Gagnon V, Van Themsche C, Turner S, Leblanc V and Asselin E: Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 13: 259-271, 2008.
15. Yu C, Zhang X, Sun G, et al: RNA Interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. J Cell Mol Med (In press).
16. Quan H, Xu Y and Lou L: p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. Int J Cancer 122: 1730-1737, 2008.
17. Alldinger I, Dittert D, Peiper M, et al: Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology 5: 370-379, 2005.
18. Yu GR, Kim SH, Park SH, et al: Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Exp Mol Med 39: 641-652, 2007.
19. Kotzsch M, Sieuwerts AM, Grosser M, et al: Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res Treat 111: 229-240, 2008.
20. Spinella F, Rosano L, Di Castro V, Natali PG and Bagnato A: Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 279: 46700-46705, 2004.
21. Jenkins Y, Markovtsov V, Lang W, et al: Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell 16: 5621-5629, 2005.
22. Heissig B, Hattori K, Friedrich M, Rafii S and Werb Z: Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. Curr Opin Hematol 10: 136-141, 2003.
23. Ahn GO and Brown JM: Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13: 193-205, 2008.
24. Lutzky VP, Carnevale RP, Alvarez MJ, et al: Platelet-endothelial cell adhesion molecule-1 (CD31) recycles and induces cell growth inhibition on human tumor cell lines. J Cell Biochem 98: 1334-1350, 2006.
25. Friedrich K, Wieder T, Von Haefen C, et al: Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 20: 2749-2760, 2001.
26. Nathan SS, DiResta GR, Casas-Ganem JE, et al: Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 11: 2389-2397, 2005.
27. Hellawell GO, Ferguson DJ, Brewster SF and Macaulay VM: Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int 91: 271-277, 2003.
28. Woods CM, Zhu J, McQueney PA, Bollag D and Lazarides E: Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1: 506-526, 1995.
29. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H and Wilson L: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825, 1996.
30. Wang TH, Wang HS and Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88: 2619-2628, 2000.
31. Gergely F, Karlsson C, Still I, Cowell J, Kilmartin J and Raff JW: The TACC domain identifies a family of centrosomal proteins that can interact with microtubules. Proc Natl Acad Sci USA 97: 14352-14357, 2000.
32. Kinoshita K, Noetzel TL, Pelletier L, et al: Aurora A phosphorylation of TACC3/maskin is required for centrosome-dependent microtubule assembly in mitosis. J Cell Biol 170: 1047-1055, 2005.
33. Fukasawa K: Centrosome amplification, chromosome instability and cancer development. Cancer Lett 230: 6-19, 2005.
34. Gergely F, Draviam VM and Raff JW: The ch-TOG/XMAP215 protein is essential for spindle pole organization in human somatic cells. Genes Dev 17: 336-341, 2003.
35. Schneider L, Essmann F, Kletke A, et al: The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival. J Biol Chem 282: 29273-29283, 2007.
36. Giannakakou P, Robey R, Fojo T and Blagosklonny MV: Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20: 3806-3813, 2001.
37. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
38. Fan S, Cherney B, Reinhold W, Rucker K and O'Connor PM: Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 4: 1047-1054, 1998.
39. Bacus SS, Gudkov AV, Lowe M, et al: Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20: 147-155, 2001.
40. Asakuma J, Sumitomo M, Asano T, Asano T and Hayakawa M: Selective Akt inactivation and tumor necrosis factor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 63: 1365-1370, 2003.